Prime Medicine
Develops Prime Editing therapies for liver, lung, and partnered cell-therapy programs.
$3.59
After-hours close−0.02 (−0.61%)
At close$3.61(−0.77%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.23 | — | — |
| Aug 2026 | −$0.26 | −$0.24 | +6.7% |
| May 2026 | −$0.24 | −$0.28 | −16.7% |
| Mar 2026 | −$0.25 | −$0.22 | +12.0% |
| Nov 2025 | −$0.28 | −$0.32 | −14.3% |
The latest year is open to everyone — the 20 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Oct 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Jan 2021 | |||
| Dec 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | −$0.23 | — | — | $1.3M | — | — |
| Aug 6, 2026 | −$0.26 | −$0.24 | +6.7% | $2.3M | $1.2M | −48.7% |
| May 7, 2026 | −$0.24 | −$0.28 | −16.7% | $2.3M | $856.0K | −63.2% |
| Mar 3, 2026 | −$0.25 | −$0.22 | +12.0% | $1.3M | $842.0K | −34.6% |
| Nov 7, 2025 | −$0.28 | −$0.32 | −14.3% | $2.1M | $1.2M | −40.3% |
The latest year is open to everyone — the 20 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 28, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 10, 2024 | ||||||
| Mar 1, 2024 | ||||||
| Nov 3, 2023 | ||||||
| Aug 7, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 9, 2023 | ||||||
| Oct 21, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Jan 1, 2021 | ||||||
| Dec 31, 2019 | ||||||